GlassScriptPhysician profile
John P Galvin
NPI 1578724092
$6,512.37
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,244 · 2020: $4,223 · 2021: $44.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $6,073.59 | 2019-2020 | |
| Seagen INC. | $125.18 | 2019-2021 | |
| Amgen INC. | $124.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $120.47 | 2019 | |
| Genentech USA, INC. | $24.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.77 | 2020 | |
| Kite Pharma, INC. | $18.75 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Galvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.